ArticleGynecologic oncology reports2017

Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits.

Abigail S Zamorano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.